Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

Completed

Conditions studied: Chronic Kidney Failure

In brief

A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also referred to as enteric toxin reduction technology. Our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (Kibow® Biotics/RenadylTM) as a dietary supplement product for patients undergoing standardized care of treatment for their CKD stage 3 and stage 4 conditions.

Key facts

Study ID

NCT01450657

Run by

Kibow Pharma

People needed

31

Starts

2011-07-01

Expected to finish

2012-10-01

Last updated by the study team

2017-08-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 75 years
• CKD Stages 3 and 4 as documented by prior medical history
• Serum Creatinine >2.5 mg/dL
• Stable and on CKD status 3 and 4 at least for a year or more

You may not qualify if…

• Pregnant or nursing women
• Refusal to sign the informed consent form
• Documented to have HIV/AIDS/Liver disease
• Active dependency on drugs or alcohol
• Any non-related medical, debilitating disease/disorder that would interfere with adherence to this study
• Currently on anticoagulant therapy

Where it is running

• Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.